Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Brigham and Women's Hospital | OTHER |
| Harvard Medical School (HMS and HSDM) | OTHER |
Not provided
Not provided
Not provided
Not provided
This observational study is designed to provide a better understanding of the potential use of interferon gamma (IFNγ) and IFNγ-inducible chemokines as markers of HLH disease activity in adults, and the potential of IFNγ to represent a therapeutic target.
This is a observational study designed to determine the levels of pro-inflammatory markers in adult patients diagnosed with HLH and to assess the relationship between the biomarkers and disease activity in these patients during the HLH course. Inflammatory markers include IFNγ and IFNγ-induced chemokines C-X-C chemokine ligand 9 and C-X-C chemokine ligand 10.
In addition to the blood samples for the biomarker analysis, relevant information gathered by the treating physician will be collected in a data collection form. Whenever possible, collection of serum samples for biomarker analysis and relevant information should occur at HLH diagnosis, at regular time intervals during the treatment course (not more than once a week) up to resolution of HLH.
Blood samples will also be sent to the study sponsor (NovImmune S.A.) for cytokine testing. Before patient's samples are sent to the sponsor for testing, patient's name and any personal identifying information will be coded to protect participant's privacy.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A-HLH Patients | Patients diagnosed with A-HLH. |
| |
| Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH) Patients | Patients diagnosed with HLH in the context of a malignancy. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Blood Draws Data Collection | Other |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 10 (CXCL10) | Serum samples was collected at various times after HLH diagnosis to determine the concentration of CXCL10. | 11 months |
| Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 9 (CXCL9) | Serum samples was collected at various times after HLH diagnosis to determine the concentration of CXCL9. | 11 months |
| Mean Serum Concentration of Inflammatory Biomarker - Interferon Gamma (IFNg) | Serum samples was collected at various times after HLH diagnosis to determine the concentration of IFNg. | 11 months |
| Mean Serum Concentration of Inflammatory Biomarker - Interleukin 10 (IL-10) | Serum samples was collected at various times after HLH diagnosis to determine the concentration of IL-10. | 11 months |
| Mean Serum Concentration of Inflammatory Biomarker - Interleukin 1 Beta (IL-1B) | Serum samples was collected at various times after HLH diagnosis to determine the concentration of IL-1B. | 11 months |
| Mean Serum Concentration of Inflammatory Biomarker - Interleukin 6 (IL-6) | Serum samples was collected at various times after HLH diagnosis to determine the concentration of IL-6. | 11 months |
| Mean Serum Concentration of Inflammatory Biomarker - Neopterin |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Male and female adult (>=18 years old) patients who are diagnosed with HLH and meet the inclusion criteria.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nancy Berliner, MD | Brigham and Women's Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | United States |
Not provided
| Label | URL |
|---|---|
| Brigham and Women's Hospital | View source |
Not provided
A total of 14 patients were enrolled in the study.
This Phase 4 observational study was conducted in adult patients diagnosed with hemophagocytic lymphohistiocytosis (A-HLH) at a single center in the United States of America.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | A-HLH Patients | Patients diagnosed with A-HLH. |
| FG001 | Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH) Patients | Patients diagnosed with HLH in the context of a malignancy. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
The enrolled set included all patients who signed an informed consent.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | A-HLH Patients | Patients diagnosed with A-HLH. |
| BG001 | M-HLH Patients | Patients diagnosed with HLH in the context of a malignancy. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 10 (CXCL10) | Serum samples was collected at various times after HLH diagnosis to determine the concentration of CXCL10. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | picogram/milliliter (pg/mL) | 11 months |
|
Not provided
Adverse events collection is not applicable as this is an observational study. Safety analysis including all-cause mortality, serious adverse events and other (non-serious) adverse events were not monitored.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | A-HLH Patients | Patients diagnosed with A-HLH. | 0 |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Medical Director | Swedish Orphan Biovitrum | +4686972000 | clinical@sobi.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Dec 6, 2021 | Apr 23, 2024 | Prot_002.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | May 31, 2021 | Aug 25, 2023 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D051359 | Lymphohistiocytosis, Hemophagocytic |
| ID | Term |
|---|---|
| D015616 | Histiocytosis, Non-Langerhans-Cell |
| D015614 | Histiocytosis |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
For biomarker analysis a maximum of 5 milliliter (mL) of whole blood was required per time point.
Serum samples was collected at various times after HLH diagnosis to determine the concentration of neopterin.
| 11 months |
| Mean Serum Concentration of Inflammatory Biomarker - Tumor Necrosis Factor Alpha (TNFa) | Serum samples was collected at various times after HLH diagnosis to determine the concentration of TNFa. | 11 months |
| Mean Serum Concentration of Inflammatory Biomarker - Total Human Interferon Gamma (hIFNg) | Serum samples was collected at various times after HLH diagnosis to determine the concentration of hIFNg. | 11 months |
| Mean Serum Concentration of Inflammatory Biomarker - Soluble CD163 (sCD163) | Serum samples was collected at various times after HLH diagnosis to determine the concentration of sCD163. | 11 months |
| Mean Serum Concentration of Inflammatory Biomarker - Soluble IL-2 Receptor Alpha (sIL2Ra) | Serum samples was collected at various times after HLH diagnosis to determine the concentration of sIL2Ra. | 11 months |
| Mean Serum Concentration of White Blood Cells | Blood samples was collected at various times after HLH diagnosis to determine the concentration of white blood cells. | 11 months |
| Mean Serum Concentration of Red Blood Cells | Blood samples was collected at various times after HLH diagnosis to determine the concentration of red blood cells. | 11 months |
| Mean Serum Concentration of Hemoglobin | Blood samples was collected at various times after HLH diagnosis to determine the concentration of hemoglobin. | 11 months |
| Mean Serum Concentration of Hematocrit | Blood samples was collected at various times after HLH diagnosis to determine the concentration of hematocrit. | 11 months |
| Mean Serum Concentration of Platelets | Blood samples was collected at various times after HLH diagnosis to determine the concentration of platelets. | 11 months |
| Mean Serum Concentration of Neutrophils | Blood samples was collected at various times after HLH diagnosis to determine the concentration of neutrophils. | 11 months |
| Mean Serum Concentration of Lymphocytes | Blood samples was collected at various times after HLH diagnosis to determine the concentration of lymphocytes. | 11 months |
| Mean Serum Concentration of Monocytes | Blood samples was collected at various times after HLH diagnosis to determine the concentration of monocytes. | 11 months |
| Mean Serum Concentration of Eosinophils | Blood samples was collected at various times after HLH diagnosis to determine the concentration of eosinophils. | 11 months |
| Mean Serum Concentration of Basophils | Blood samples was collected at various times after HLH diagnosis to determine the concentration of basophils. | 11 months |
| Mean Plasma Concentration of D-Dimer | Blood samples was collected at various times after HLH diagnosis to determine the concentration of D-dimer. | 11 months |
| Mean Plasma Concentration of Fibrinogen | Blood samples was collected at various times after HLH diagnosis to determine the concentration of fibrinogen. | 11 months |
| Mean Activated Partial Thromboplastin Time (aPTT) | Blood samples was collected at various times after HLH diagnosis to determine the aPTT. | 11 months |
| Mean Prothrombin Time | Blood samples was collected at various times after HLH diagnosis to determine the prothrombin time. | 11 months |
| Mean Serum Concentration of C-Reactive Protein | Blood samples was collected at various times after HLH diagnosis to determine the concentration of c-reactive protein. | 11 months |
| Mean Serum Concentration of Ferritin | Blood samples was collected at various times after HLH diagnosis to determine the concentration of ferritin. | 11 months |
| Mean Plasma Concentration of Blood Urea Nitrogen | Blood samples was collected at various times after HLH diagnosis to determine the concentration of blood urea nitrogen. | 11 months |
| Mean Serum Concentration of Creatinine | Blood samples was collected at various times after HLH diagnosis to determine the concentration of creatinine. | 11 months |
| Mean Serum Concentration of Albumin | Blood samples was collected at various times after HLH diagnosis to determine the concentration of albumin. | 11 months |
| Mean Serum Concentration of Sodium | Blood samples was collected at various times after HLH diagnosis to determine the concentration of sodium. | 11 months |
| Mean Serum Concentration of Fasting Triglycerides | Blood samples was collected at various times after HLH diagnosis to determine the concentration of fasting triglycerides. | 11 months |
| Mean Serum Concentration of Total Bilirubin | Blood samples was collected at various times after HLH diagnosis to determine the concentration of total bilirubin. | 11 months |
| Mean Serum Concentration of Conjugated Bilirubin | Blood samples was collected at various times after HLH diagnosis to determine the concentration of conjugated bilirubin. | 11 months |
| Mean Serum Concentration of Alanine Aminotransferase | Blood samples was collected at various times after HLH diagnosis to determine the concentration of alanine aminotransferase. | 11 months |
| Mean Serum Concentration of Aspartate Aminotransferase | Blood samples was collected at various times after HLH diagnosis to determine the concentration of aspartate aminotransferase. | 11 months |
| Mean Serum Concentration of Alkaline Phosphatase | Blood samples was collected at various times after HLH diagnosis to determine the concentration of alkaline phosphatase. | 11 months |
| Mean Serum Concentration of Lactate Dehydrogenase | Blood samples was collected at various times after HLH diagnosis to determine the concentration of lactate dehydrogenase. | 11 months |
| Mean Serum Concentration of Immunoglobulin G (IgG) | Blood samples was collected at various times after HLH diagnosis to determine the concentration of IgG. | 11 months |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants | No |
|
| Race/Ethnicity, Customized | Count of Participants | Participants | No |
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Primary | Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 9 (CXCL9) | Serum samples was collected at various times after HLH diagnosis to determine the concentration of CXCL9. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | pg/mL | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Inflammatory Biomarker - Interferon Gamma (IFNg) | Serum samples was collected at various times after HLH diagnosis to determine the concentration of IFNg. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | pg/mL | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Inflammatory Biomarker - Interleukin 10 (IL-10) | Serum samples was collected at various times after HLH diagnosis to determine the concentration of IL-10. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | pg/mL | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Inflammatory Biomarker - Interleukin 1 Beta (IL-1B) | Serum samples was collected at various times after HLH diagnosis to determine the concentration of IL-1B. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | pg/mL | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Inflammatory Biomarker - Interleukin 6 (IL-6) | Serum samples was collected at various times after HLH diagnosis to determine the concentration of IL-6. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | pg/mL | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Inflammatory Biomarker - Neopterin | Serum samples was collected at various times after HLH diagnosis to determine the concentration of neopterin. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | nanomoles | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Inflammatory Biomarker - Tumor Necrosis Factor Alpha (TNFa) | Serum samples was collected at various times after HLH diagnosis to determine the concentration of TNFa. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | pg/mL | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Inflammatory Biomarker - Total Human Interferon Gamma (hIFNg) | Serum samples was collected at various times after HLH diagnosis to determine the concentration of hIFNg. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | pg/mL | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Inflammatory Biomarker - Soluble CD163 (sCD163) | Serum samples was collected at various times after HLH diagnosis to determine the concentration of sCD163. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | nanogram (ng)/mL | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Inflammatory Biomarker - Soluble IL-2 Receptor Alpha (sIL2Ra) | Serum samples was collected at various times after HLH diagnosis to determine the concentration of sIL2Ra. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | pg/mL | 11 months |
|
|
|
| Primary | Mean Serum Concentration of White Blood Cells | Blood samples was collected at various times after HLH diagnosis to determine the concentration of white blood cells. | The enrolled set included all patients who signed an informed consent. | Posted | Mean | Standard Deviation | cells*10^3/microliter (mcL) | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Red Blood Cells | Blood samples was collected at various times after HLH diagnosis to determine the concentration of red blood cells. | The enrolled set included all patients who signed an informed consent. | Posted | Mean | Standard Deviation | cells*10^6/mcL | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Hemoglobin | Blood samples was collected at various times after HLH diagnosis to determine the concentration of hemoglobin. | The enrolled set included all patients who signed an informed consent. | Posted | Mean | Standard Deviation | gram/deciliter (g/dL) | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Hematocrit | Blood samples was collected at various times after HLH diagnosis to determine the concentration of hematocrit. | The enrolled set included all patients who signed an informed consent. | Posted | Mean | Standard Deviation | percentage of volume of red cells | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Platelets | Blood samples was collected at various times after HLH diagnosis to determine the concentration of platelets. | The enrolled set included all patients who signed an informed consent. | Posted | Mean | Standard Deviation | cells*10^3/mcL | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Neutrophils | Blood samples was collected at various times after HLH diagnosis to determine the concentration of neutrophils. | The enrolled set included all patients who signed an informed consent. | Posted | Mean | Standard Deviation | cells*10^3/mcL | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Lymphocytes | Blood samples was collected at various times after HLH diagnosis to determine the concentration of lymphocytes. | The enrolled set included all patients who signed an informed consent. | Posted | Mean | Standard Deviation | cells*10^3/mcL | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Monocytes | Blood samples was collected at various times after HLH diagnosis to determine the concentration of monocytes. | The enrolled set included all patients who signed an informed consent. | Posted | Mean | Standard Deviation | cells*10^3/mcL | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Eosinophils | Blood samples was collected at various times after HLH diagnosis to determine the concentration of eosinophils. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | cells*10^3/mcL | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Basophils | Blood samples was collected at various times after HLH diagnosis to determine the concentration of basophils. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | cells*10^3/mcL | 11 months |
|
|
|
| Primary | Mean Plasma Concentration of D-Dimer | Blood samples was collected at various times after HLH diagnosis to determine the concentration of D-dimer. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | microgram (mcg)/mL | 11 months |
|
|
|
| Primary | Mean Plasma Concentration of Fibrinogen | Blood samples was collected at various times after HLH diagnosis to determine the concentration of fibrinogen. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | milligram (mg)/dL | 11 months |
|
|
|
| Primary | Mean Activated Partial Thromboplastin Time (aPTT) | Blood samples was collected at various times after HLH diagnosis to determine the aPTT. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | seconds | 11 months |
|
|
|
| Primary | Mean Prothrombin Time | Blood samples was collected at various times after HLH diagnosis to determine the prothrombin time. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | seconds | 11 months |
|
|
|
| Primary | Mean Serum Concentration of C-Reactive Protein | Blood samples was collected at various times after HLH diagnosis to determine the concentration of c-reactive protein. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | mg/dL | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Ferritin | Blood samples was collected at various times after HLH diagnosis to determine the concentration of ferritin. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | ng/mL | 11 months |
|
|
|
| Primary | Mean Plasma Concentration of Blood Urea Nitrogen | Blood samples was collected at various times after HLH diagnosis to determine the concentration of blood urea nitrogen. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | mg/dL | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Creatinine | Blood samples was collected at various times after HLH diagnosis to determine the concentration of creatinine. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | mg/dL | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Albumin | Blood samples was collected at various times after HLH diagnosis to determine the concentration of albumin. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | gram/dL | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Sodium | Blood samples was collected at various times after HLH diagnosis to determine the concentration of sodium. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | millimoles/L | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Fasting Triglycerides | Blood samples was collected at various times after HLH diagnosis to determine the concentration of fasting triglycerides. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | mg/dL | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Total Bilirubin | Blood samples was collected at various times after HLH diagnosis to determine the concentration of total bilirubin. | The enrolled set included all patients who signed an informed consent. | Posted | Mean | Standard Deviation | mg/dL | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Conjugated Bilirubin | Blood samples was collected at various times after HLH diagnosis to determine the concentration of conjugated bilirubin. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | mg/dL | 11 months | Samples | Samples |
|
|
|
| Primary | Mean Serum Concentration of Alanine Aminotransferase | Blood samples was collected at various times after HLH diagnosis to determine the concentration of alanine aminotransferase. | The enrolled set included all patients who signed an informed consent. | Posted | Mean | Standard Deviation | international units (IU)/L | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Aspartate Aminotransferase | Blood samples was collected at various times after HLH diagnosis to determine the concentration of aspartate aminotransferase. | The enrolled set included all patients who signed an informed consent. | Posted | Mean | Standard Deviation | IU/L | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Alkaline Phosphatase | Blood samples was collected at various times after HLH diagnosis to determine the concentration of alkaline phosphatase. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | IU/L | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Lactate Dehydrogenase | Blood samples was collected at various times after HLH diagnosis to determine the concentration of lactate dehydrogenase. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | IU/L | 11 months |
|
|
|
| Primary | Mean Serum Concentration of Immunoglobulin G (IgG) | Blood samples was collected at various times after HLH diagnosis to determine the concentration of IgG. | The enrolled set included all patients who signed an informed consent. Only patients with data collected for this outcome measure are reported. | Posted | Mean | Standard Deviation | mg/dL | 11 months |
|
|
|
| 0 |
| 0 |
| 0 |
| 0 |
| 0 |
| EG001 | M-HLH Patients | Patients diagnosed with HLH in the context of a malignancy. | 0 | 0 | 0 | 0 | 0 | 0 |
Not provided
Not provided